Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Investigating Role Of Brain Tumors In Deafness
Researchers at the Peninsula Medical School have received a grant of over ÷£39,000 from the charity Deafness Research UK, to investigate the role of brain tumours causing deafness in children and adults and the development of therapies using in vitro models.
generic viagra online
FDA Requests Labeling Change For Leukotriene Modifiers
The U.S. Food and Drug Administration provided further updated safety information on a class of asthma drugs known as leukotriene modifiers. The FDA has requested that manufacturers include a precaution in the drug prescribing information (drug labeling) regarding neuropsychiatric events (behavior, mood changes) that have been reported in some persons taking montelukast (Singulair), zafirlukast (Accolate), and zileuton (Zyflo and Zyflo CR).
News of the day
Understanding The Process Of Homosexual Identity Formation Among Asian And Pacific Islander Youth
Young American-raised Asian and Pacific Islanders (API), who are in the sexual minority, face psychological and social stresses in dealing with their families" values and ancestral cultures that significantly impact the development of their ethnic and sexual identities.
Cardiovascular

International Workshop Assesses Revisions Aimed At The Purity, Quality Of Blood Thinner

Continuing to help ensure the identity, purity and quality of heparin, the U.S. Pharmacopeial (USP) Convention has revised written and physical standards for the widely used blood thinner. In February, USP released updated heparin standards at the request of the Food and Drug Administration (FDA) in response to the 2008 public health crisis in which more than 200 people died as a result of heparin adulterated for economic gain. A second phase of revisions is reflected in the newly posted standards. These developments and new information about heparin were discussed by scientists and regulators at the third International Heparin Workshop held at USP headquarters in Rockville, Maryland, July 27. "While financially-motivated adulteration of medicines is a distressingly persistent problem," noted Roger L. Williams, M.D., USP"s chief executive officer, "I"m pleased at the progress we"ve made in helping to ensure that such tragic events are minimized. Stronger methods for detecting a range of potential contaminants have been thoroughly assessed and incorporated into the new test methods, and the new physical reference standards are specific to these methods. Manufacturers - and in consequence, physicians and their patients - can feel more confident of the purity and integrity of their heparin products." The Workshop, co-sponsored by USP, the British National Institute of Biological Standards and Control (NIBSC), and the European Directorate for the Quality of Medicines (EDQM), reflected the global nature of both the problem of adulteration and the res cooperating to combat it, with attendees from more than 17 countries. The updated written standards are the Heparin Sodium Stage 2 Monograph and the Heparin Sodium Injection Stage 2 Monograph; new reference standards are Heparin Sodium for Assays, Oversulfated Chondroitin Sulfate, and Dermatan Sulfate. These and other related standards and information are available at http://www.usp.org/hottopics/heparin.html. The new standards will become official on October 1, 2009. Francine Pierson US Pharmacopeia


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009